New drug combo aims to control myeloma without transplant
NCT ID NCT04656951
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests daratumumab (Darzalex) combined with other drugs as a first treatment for multiple myeloma patients who are not eligible for a stem cell transplant. The goal is to see if this combination can achieve very good partial remission or better after 8 cycles, and then control the disease with maintenance therapy. If the cancer returns, patients will be retreated with daratumumab. The study involves 67 participants and is currently active but not recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Daratumumab (Darzalex) combined with bortezomib, cyclophosphamide, dexamethasone, and lenalidomide
What this could lead to
If successful, this could provide a treatment plan that controls multiple myeloma for longer without needing a stem cell transplant.
What could go wrong
This is a small, early-phase trial with only 67 participants, so results may not apply to everyone. The disease may still relapse despite treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Cologne
Cologne, 50937, Germany